Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 19/20 | 0.54 |
| ▸ | CASP6 | P55212 | 18/20 | 0.54 |
| ▸ | CASP8 | Q14790 | 18/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17494193 | 1.00 | CASP3 (0.54) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL17494192 | 1.00 | CASP3 (0.54) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL11896297 | 0.94 | CASP3 (0.49) | CASP3CASP6CASP8 | |
| SCHEMBL11896298 | 0.94 | CASP3 (0.49) | CASP3CASP6CASP8 | |
| SCHEMBL11896299 | 0.94 | CASP3 (0.49) | CASP3CASP6CASP8 | |
| SCHEMBL11911364 | 0.94 | CASP3 (0.49) | CASP3CASP6CASP8 | |
| SCHEMBL2878062 | 0.94 | CASP3 (0.49) | CASP3CASP6CASP8 | |
| SCHEMBL2878064 | 0.94 | CASP3 (0.49) | CASP3CASP6CASP8 | |
| SCHEMBL20870231 | 0.94 | CASP3 (0.49) | CASP3CASP6CASP8 | |
| SCHEMBL15947165 | 0.92 | CASP3 (0.63) | CASP3CASP6CASP8CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612163-B2 | Stabilization of whole blood samples | THE GENERAL HOSPITAL CORPORATION (US) | 2023-03-28 | — | — | US | claimed |
| WO-2022123062-A1 | BLOCKING CASPASE AND/OR FASL FOR PREVENTING FATAL OUTCOME IN COVID-19 PATIENTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-06-16 | — | — | WO | claimed |
| US-20210007348-A1 | STABILIZATION OF WHOLE BLOOD SAMPLES | THE GENERAL HOSPITAL CORPORATION | 2021-01-14 | — | — | US | claimed |
| EP-3698628-A1 | STABILIZATION OF WHOLE BLOOD SAMPLES | The General Hospital Corporation (US) | 2020-08-26 | — | — | EP | claimed |
| EP-3177924-A1 | STABILIZATION OF WHOLE BLOOD SAMPLES | The General Hospital Corporation (US) | 2017-06-14 | — | — | EP | claimed |
| WO-2016022433-A1 | STABILIZATION OF WHOLE BLOOD SAMPLES | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-11 | — | — | WO | claimed |
| US-20250099530-A1 | COMPOUND FOR USE IN PREVENTING AND/OR TREATING AN INFECTION CAUSED BY SARS-COV-2 | UNIVERSITÉ PARIS CITÉ (FR) | 2025-03-27 | — | — | US | disclosed |
| EP-4469073-A1 | COMPOUND FOR USE IN PREVENTING AND/OR TREATING AN INFECTION CAUSED BY SARS-COV-2 | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2024-12-04 | — | — | EP | disclosed |
| CN-119072326-A | Compounds for preventing and/or treating infections caused by SARS-CoV-2 | INSERM(法国国家健康医学研究院) | 2024-12-03 | — | — | CN | disclosed |
| US-20240382628-A1 | COMPOSITIONS AND METHODS RELATING TO CELLS WITH ADHERED PARTICLES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4370160-A1 | COMPOSITIONS AND METHODS RELATING TO CELLS WITH ADHERED PARTICLES | President And Fellows Of Harvard College (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023139182-A1 | COMPOUND FOR USE IN PREVENTING AND/OR TREATING AN INFECTION CAUSED BY SARS-COV-2 | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-07-27 | — | — | WO | disclosed |
| US-11612163-B2 | Stabilization of whole blood samples | THE GENERAL HOSPITAL CORPORATION (US) | 2023-03-28 | — | — | US | disclosed |
| WO-2020264313-A1 | COMPOSITIONS FOR THE STABILIZATION OF CELL-FREE NUCLEIC ACIDS AND METHODS THEREOF | ZYMO RESEARCH CORPORATION (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-3698628-A1 | STABILIZATION OF WHOLE BLOOD SAMPLES | The General Hospital Corporation (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10750739-B2 | Stabilization of whole blood samples | THE GENERAL HOSPITAL CORPORATION (US) | 2020-08-25 | — | — | US | disclosed |
| US-20170223949-A1 | STABILIZATION OF WHOLE BLOOD SAMPLES | THE GENERAL HOSPITAL CORPORATION | 2017-08-10 | — | — | US | disclosed |
| EP-3177924-A1 | STABILIZATION OF WHOLE BLOOD SAMPLES | The General Hospital Corporation (US) | 2017-06-14 | — | — | EP | disclosed |
| CN-106796219-A | The stabilisation of whole blood sample | 通用医疗公司 | 2017-05-31 | — | — | CN | disclosed |
| WO-2016022433-A1 | STABILIZATION OF WHOLE BLOOD SAMPLES | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099530-A1 | COMPOUND FOR USE IN PREVENTING AND/OR TREATING AN INFECTION CAUSED BY SARS-COV-2 | ACE2, ACE, SARS1 | CASP3 426/4885CASP6 220/4885CASP8 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.